Compare Carvana Co (CVNA) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carvana Co vs Quest Diagnostics Inc — how do they compare? Carvana Co trades at $63.73 (market cap $69.55B), while Quest Diagnostics Inc trades at $230.97 (market cap $25.48B). The key difference: Carvana Co is far larger — about 2.7× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Carvana Co pays none. Which is the better fit depends on your goals — on Pluang, investors hold Carvana Co for 28 Days and Quest Diagnostics Inc for 56 Days on average.
| CVNA | DGX | |
|---|---|---|
Market Cap | $69.55B | $25.48B |
Volume | 7,671,750 | 941,866 |
Sector | Consumer Cyclical | Health |
52-Week High | $95.69 | $247.45 |
52-Week Low | $56.27 | $173.49 |
Typical Hold Time | 28 Days | 56 Days |
Enterprise Value | $72.04B | $31.23B |
Dividend Yield | — | 1.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carvana (CVNA) trades at $63.21, up 0.72% on the day, with a mixed technical picture showing bearish moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 revenue up 52% and net income of $1.41 billion in 2025. Analyst sentiment is divided, with a consensus price target of $84.07, but technical indicators suggest near-term resistance at $64.
The outlook for CVNA hinges on sustained revenue growth and margin expansion, supported by operational improvements and capacity expansions. Key risks include high debt levels, competitive pressures, and sensitivity to interest rates. Upside potential exists if the company continues to exceed earnings expectations and expand its market share in the online used car sector.
Quest Diagnostics (DGX) trades at $230.81, up 1.68% with strong year-to-date performance driven by organic growth and advanced diagnostics adoption. The company has consistently beaten earnings expectations in recent quarters with Q2 2026 EPS of $3.12 exceeding estimates. Technical indicators show a bearish bias while fundamentals remain solid with 9.19% net margin and 14.35% ROE. Recent developments include a partnership with Apple Health app and positive clinical study results.
DGX presents a mixed outlook with strong fundamental performance offset by technical weakness and regulatory headwinds. The 38% upside to consensus price target of $250 offers potential, but Medicare reimbursement cuts and bearish technical signals warrant caution. Growth in consumer testing and strategic partnerships provide catalysts, though execution risks and debt levels require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Carvana Co
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
